Allelic ratio of KRAS mutations in pancreatic cancer

Oncologist

Volumn 20, Issue 4, 2015, Pages e8-e9

  Lennerz, Jochen K ^a   Stenzinger, Albrecht ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN KINASE INHIBITOR;

GENE FREQUENCY; HUMAN; LETTER; MUTATION; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; GENETICS; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS;

HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84927637709     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0408     Document Type: Letter

References (10)

1. ChiuJW, Wong H, LeungRetal. Advancedpancreatic cancer: Flourishingnovel approaches in the era of biological therapy. The Oncologist 2014; 19: 937-950.
2. Stephen AG, Esposito D, Bagni RK et al. Dragging ras back in the ring. Cancer Cell 2014; 25: 272-281.
3. Garcea G, Neal CP, Pattenden CJ et al. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur J Cancer 2005; 41: 2213-2236.
4. BiankinAV, Waddell N, Kassahn KS et al. Pancreatic cancergenomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405.
5. Tsiatis AC, Norris-Kirby A, RichRG et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: Diagnostic and clinical implications. JMol Diagn 2010; 12: 425-432.
6. Sims D, Sudbery I, Ilott NE et al. Sequencing depth and coverage: Key considerations in genomic analyses. Nat Rev Genet 2014; 15: 121-132.
7. Song S, Nones K, Miller D et al. qpure: A tool to estimate tumor cellularity fromgenome-wide single-nucleotide polymorphism profiles. PLoSOne 2012; 7: e45835.
8. Boeck S, Ormanns S, Haas M et al. Translational research in pancreatic cancer: KRAS and beyond. Pancreas 2014; 43: 150-152.
9. Carter SL, Cibulskis K, Helman E et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-421.
10. Chabner BA, Ellisen LW, Iafrate AJ. Personalized medicine: Hype or reality. The Oncologist 2013; 18: 640-643.